Translational Development Acquisition Corp.
TDAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Market Cap | $40,541 | $40,541 | $40,541 |
| - Cash | $438 | $2 | $2 |
| + Debt | $6,110,777,000 | $348 | $259 |
| Enterprise Value | $6,110,817,102 | $40,886 | $40,797 |
| Revenue | $1,065,788,000 | $0 | $0 |
| % Growth | – | – | – |
| Gross Profit | $744,919,000 | $0 | $0 |
| % Margin | 69.9% | – | – |
| EBITDA | -$71 | -$486 | $0 |
| % Margin | -0% | – | – |
| Net Income | -$71 | -$486 | -$71 |
| % Margin | -0% | – | – |
| EPS Diluted | -0.016 | -0.12 | -0.017 |
| % Growth | 86.5% | -589.7% | – |
| Operating Cash Flow | -$851 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | $0 |
| Free Cash Flow | -$851 | -$0 | -$0 |